J Natl Compr Canc Netw

• 

  Publication Venue For

  • Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology..  21:67-81. 2023
  • NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023..  20:1288-1298. 2022
  • Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study..  20:1255-1266.e11. 2022
  • NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022..  20:1204-1214. 2022
  • Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology..  20:1267-1275. 2022
  • Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis..  20:1099-1106.e2. 2022
  • Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia..  20:1116-1123. 2022
  • Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology..  20:925-951. 2022
  • NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022..  20:754-764. 2022
  • Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology..  20:815-833. 2022
  • Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology..  20:691-722. 2022
  • NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022..  20:622-634. 2022
  • Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016..  20:379-386.e9. 2022
  • T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology..  20:285-308. 2022
  • Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology..  20:167-192. 2022
  • NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022..  19:1382-1394. 2021
  • Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..  19:1277-1303. 2021
  • NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021..  19:1218-1230. 2021
  • Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..  19:1181-1201. 2021
  • NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021..  19:1006-1019. 2021
  • NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021..  19:888-895. 2021
  • NCCN Guidelines® Insights: Palliative Care, Version 2.2021..  19:780-788. 2021
  • Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..  19:839-868. 2021
  • Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..  19:541-565. 2021
  • NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021..  19:364-376. 2021
  • Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..  19:329-359. 2021
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021..  19:254-266. 2021
  • Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..  19:191-226. 2021
  • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology..  19:77-102. 2021
  • NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021..  19:16-27. 2021
  • Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology..  18:1685-1717. 2020
  • NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021..  18:1604-1612. 2020
  • Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology..  18:1537-1570. 2020
  • NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021..  18:1460-1467. 2020
  • Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology..  18:1248-1269. 2020
  • Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma..  18:1087-1095. 2020
  • Current Practices for Screening and Management of Financial Distress at NCCN Member Institutions..  18:825-831. 2020
  • Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..  18:873-898. 2020
  • NCCN Guidelines Insights: Rectal Cancer, Version 6.2020..  18:806-815. 2020
  • Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..  18:755-781. 2020
  • NCCN Guidelines Insights: Cervical Cancer, Version 1.2020..  18:660-666. 2020
  • What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy..  18:676-681. 2020
  • Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..  18:599-634. 2020
  • NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020..  18:522-536. 2020
  • NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020..  18:380-391. 2020
  • Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology..  18:329-354. 2020
  • NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020..  18:230-241. 2020
  • Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts..  18:250-259. 2020
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology..  18:185-217. 2020
  • NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019..  18:120-131. 2020
  • Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..  18:81-112. 2020
  • Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis..  18:52-58. 2020
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020..  17:1464-1472. 2019
  • Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology..  17:1529-1554. 2019
  • Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..  17:1374-1391. 2019
  • NCCN Guidelines Insights: Kidney Cancer, Version 2.2020..  17:1278-1285. 2019
  • NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020..  17:1154-1165. 2019
  • Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology..  17:1109-1133. 2019
  • Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology..  17:977-1007. 2019
  • Authors' Reply..  17:xxxixa-xl. 2019
  • NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019..  17:896-909. 2019
  • Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..  17:855-883. 2019
  • Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology..  17:721-749. 2019
  • NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019..  17:650-661. 2019
  • Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..  17:479-505. 2019
  • Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..  17:367-402. 2019
  • Guidelines Insights: Hepatobiliary Cancers, Version 2.2019..  17:302-310. 2019
  • Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011..  17:245-254. 2019
  • Management of Immunotherapy-Related Toxicities, Version 1.2019..  17:255-289. 2019
  • Pancreatic Adenocarcinoma, Version 1.2019..  17:202-210. 2019
  • Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry..  17:127-139. 2019
  • NCCN Guidelines Insights: Breast Cancer, Version 3.2018..  17:118-126. 2019
  • Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology..  17:64-84. 2019
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019..  17:12-20. 2019
  • NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018..  16:1429-1440. 2018
  • Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology..  16:1500-1537. 2018
  • NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018..  16:1289-1303. 2018
  • Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology..  16:1108-1135. 2018
  • NCCN Guidelines Insights: Bladder Cancer, Version 5.2018..  16:1041-1053. 2018
  • Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..  16:852-871. 2018
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018..  16:807-821. 2018
  • Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..  16:874-901. 2018
  • Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology..  16:742-774. 2018
  • NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018..  16:693-702. 2018
  • Management of Locoregional Rectal Cancer..  16:617-619. 2018
  • NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018..  16:479-490. 2018
  • Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..  16:536-563. 2018
  • Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology..  16:412-441. 2018
  • NCCN Guidelines Insights: Colon Cancer, Version 2.2018..  16:359-369. 2018
  • NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening..  16:444-449. 2018
  • Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology..  16:310-320. 2018
  • NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018..  16:245-254. 2018
  • Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study..  16:267-273. 2018
  • Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer..  16:201-209. 2018
  • NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018..  16:123-135. 2018
  • Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology..  16:170-199. 2018
  • Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..  16:66-97. 2018
  • NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018..  16:11-20. 2018
  • Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..  15:1520-1541. 2017
  • Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..  15:1414-1427. 2017
  • NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017..  15:1331-1345. 2017
  • NCCN Guidelines Insights: Palliative Care, Version 2.2017..  15:989-997. 2017
  • Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..  15:1028-1061. 2017
  • Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology..  15:926-957. 2017
  • Developments in Molecular Testing and Biosimilars..  15:772-782. 2017
  • Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..  15:804-834. 2017
  • NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017..  15:761-770. 2017
  • Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology..  15:608-638. 2017
  • NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017..  15:563-573. 2017
  • Reply to 'It May be Time to Abandon Urine Tests for Bladder Cancer'..  15:lxx-lxxii. 2017
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017..  15:293-311. 2017
  • Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology..  15:230-269. 2017
  • NCCN Guidelines Insights: Bone Cancer, Version 2.2017..  15:155-167. 2017
  • Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..  15:60-87. 2017
  • NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017..  14:1505-1512. 2016
  • NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016..  14:1357-1370. 2016
  • Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology..  14:1430-1468. 2016
  • Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening..  14:1479-1485. 2016
  • Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology..  14:1286-1312. 2016
  • NCCN Guidelines Insights: Bladder Cancer, Version 2.2016..  14:1213-1224. 2016
  • NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016..  14:1067-1079. 2016
  • Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology..  14:1134-1163. 2016
  • Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures..  14:993-998. 2016
  • NCCN Guidelines Insights: Melanoma, Version 3.2016..  14:945-958. 2016
  • NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016..  14:825-836. 2016
  • Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology..  14:758-786. 2016
  • Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology..  14:574-597. 2016
  • NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016..  14:509-519. 2016
  • Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology..  14:450-473. 2016
  • NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016..  14:389-400. 2016
  • A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments..  14:311-319. 2016
  • Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology..  14:324-354. 2016
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016..  14:255-264. 2016
  • Diffuse Large B-Cell Lymphoma Version 1.2016..  14:196-231. 2016
  • Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015..  14:153-162. 2016
  • Palliative Care Version 1.2016..  14:82-113. 2016
  • Prostate Cancer, Version 1.2016..  14:19-30. 2016
  • NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015..  13:1534-1561. 2015
  • NCCN Guidelines Insights Breast Cancer, Version 1.2016..  13:1475-1485. 2015
  • Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology..  13:1398-1435. 2015
  • Anemia and Functional Disability in Older Adults With Cancer..  13:1233-1239. 2015
  • Central Nervous System Cancers, Version 1.2015..  13:1191-1202. 2015
  • Anaplastic Thyroid Carcinoma, Version 2.2015..  13:1140-1150. 2015
  • It May Be Time to Abandon Urine Tests for Bladder Cancer..  13:1163-1166. 2015
  • CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers..  13:1005-1011. 2015
  • Growth and Change at NCCN..  13:946. 2015
  • Head and Neck Cancers, Version 1.2015..  13:847-855. 2015
  • Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported?.  13:755-761. 2015
  • Rectal Cancer, Version 2.2015..  13:719-728. 2015
  • Hodgkin lymphoma, version 2.2015..  13:554-586. 2015
  • New treatment options in castration-resistant prostate cancer..  13:690-693. 2015
  • Breast Cancer Version 2.2015..  13:448-475. 2015
  • Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms..  13:424-434. 2015
  • Routine use of zoledronic acid in early-stage breast cancer..  13:480-486. 2015
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015..  13:326-362. 2015
  • Myelodysplastic syndromes, version 2.2015..  13:261-272. 2015
  • Esophageal and esophagogastric junction cancers, version 1.2015..  13:194-227. 2015
  • VATS versus open surgery for lung cancer resection: moving toward a minimally invasive approach..  13:162-164. 2015
  • Management of chemotherapy-induced neutropenia: measuring quality, cost, and value..  13:e1-e7. 2015
  • Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines..  12:1517-1523. 2014
  • Chronic myelogenous leukemia, version 1.2015..  12:1590-1610. 2014
  • Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology..  12:1454-1487. 2014
  • Palliative care, Version 1.2014. Featured updates to the NCCN Guidelines..  12:1379-1388. 2014
  • Genetic/familial high-risk assessment: breast and ovarian, version 1.2014..  12:1326-1338. 2014
  • Non-Hodgkin's lymphomas, version 4.2014..  12:1282-1303. 2014
  • Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines..  12:1211-1219. 2014
  • Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines..  12:1083-1093. 2014
  • Building the palliative care evidence base: Lessons from a randomized controlled trial of oxygen vs room air for refractory dyspnea..  12:989-992. 2014
  • Colon cancer, version 3.2014..  12:1028-1059. 2014
  • Occult primary, version 3.2014..  12:969-974. 2014
  • Gastrointestinal stromal tumors, version 2.2014..  12:853-862. 2014
  • Non-Hodgkin's lymphomas, version 2.2014..  12:916-946. 2014
  • Melanoma, version 4.2014..  12:621-629. 2014
  • Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes..  12:719-726. 2014
  • Prostate cancer, version 2.2014..  12:686-718. 2014
  • Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?.  12:821-824. 2014
  • Breast cancer version 3.2014..  12:542-590. 2014
  • Soft tissue sarcoma, version 2.2014..  12:473-483. 2014
  • Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute..  12 Suppl 1:S21-S24. 2014
  • Adolescent and young adult oncology, version 2.2014..  12:21-32. 2014
  • Senior adult oncology, version 2.2014: clinical practice guidelines in oncology ..  12:82-126. 2014
  • Prostate cancer, version 1.2014..  11:1471-1479. 2013
  • Chronic Myelogenous Leukemia, Version 1.2014..  11:1327-1340. 2013
  • Venous thromboembolic disease..  11:1402-1429. 2013
  • Moving forward with myeloid growth factors..  11:1181-1182. 2013
  • Myeloid growth factors..  11:1266-1290. 2013
  • Ovarian cancer, version 2.2013..  11:1199-1209. 2013
  • Will biosimilars gain momentum?.  11:1291-1297. 2013
  • Acute myeloid leukemia, version 2.2013..  11:1047-1055. 2013
  • Central nervous system cancers..  11:1114-1151. 2013
  • Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines..  11:917-923. 2013
  • An unusual presentation of chronic myelogenous leukemia: a review of isolated central nervous system relapse..  11:745-749. 2013
  • Breast cancer, version 3.2013: featured updates to the NCCN guidelines..  11:753-760. 2013
  • Myelodysplastic syndromes: clinical practice guidelines in oncology..  11:838-874. 2013
  • Bone cancer..  11:688-723. 2013
  • Non-small cell lung cancer, version 2.2013..  11:645-653. 2013
  • Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines..  11:531-546. 2013
  • Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines..  11:519-528. 2013
  • Multidisciplinary management of locally advanced rectal cancer: neoadjuvant approaches..  11:548-557. 2013
  • Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology..  11:562-576. 2013
  • Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis..  11:477-484. 2013
  • Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration..  11:431-441. 2013
  • Non-Hodgkin's lymphomas, version 1.2013..  11:257-272. 2013
  • Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines..  11:141-152. 2013
  • Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers..  11:60-66. 2013
  • Multiple myeloma, version 1.2013..  11:11-17. 2013
  • Small cell lung cancer..  11:78-98. 2013
  • Non-Hodgkin's Lymphomas, version 3.2012..  10:1487-1498. 2012
  • Rectal cancer..  10:1528-1564. 2012
  • Ovarian cancer, version 3.2012..  10:1339-1349. 2012
  • Non-small cell lung cancer..  10:1236-1271. 2012
  • Palliative care..  10:1284-1309. 2012
  • Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013..  10:1211-1219. 2012
  • Adolescent and young adult oncology. Clinical practice guidelines in oncology..  10:1112-1150. 2012
  • Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines..  10:1081-1087. 2012
  • NCCN Clinical Practice Guidelines Acute myeloid leukemia..  10:984-1021. 2012
  • Optimal management of malignant pleural effusions (results of CALGB 30102)..  10:975-982. 2012
  • Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines..  10:951-960. 2012
  • First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions..  10:847-856. 2012
  • Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines..  10:821-829. 2012
  • Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines..  10:703-713. 2012
  • Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme..  10:695-699. 2012
  • Cancer- and chemotherapy-induced anemia..  10:628-653. 2012
  • Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines..  10:589-597. 2012
  • The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement..  10:599-613. 2012
  • Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines..  10:449-454. 2012
  • Mucosal melanoma of the head and neck..  10:320-338. 2012
  • Senior adult oncology..  10:162-209. 2012
  • Chronic myelogenous leukemia..  10:64-110. 2012
  • Malignant pleural mesothelioma..  10:26-41. 2012
  • NCCN Clinical Practice Guidelines Occult primary..  9:1358-1395. 2011
  • Colon cancer..  9:1238-1290. 2011
  • Multiple myeloma..  9:1146-1183. 2011
  • Small cell lung cancer..  9:1086-1113. 2011
  • Hodgkin lymphoma..  9:1020-1058. 2011
  • Kidney cancer..  9:960-977. 2011
  • NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives..  9 Suppl 4:S1-22. 2011
  • Biosimilars: are they ready for primetime in the United States?.  9:934-942. 2011
  • Esophageal and esophagogastric junction cancers..  9:830-887. 2011
  • Long-term outcomes of myeloid growth factor treatment..  9:945-952. 2011
  • Myeloid growth factors..  9:914-932. 2011
  • Heparin-induced thrombocytopenia in cancer..  9:781-787. 2011
  • Venous thromboembolic disease..  9:714-777. 2011
  • Controversies in the locoregional management of head and neck cancer..  9:653-662. 2011
  • Head and neck cancers..  9:596-650. 2011
  • Non-Hodgkin's lymphomas..  9:484-560. 2011
  • A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma..  9:414-427. 2011
  • Central nervous system cancers..  9:352-400. 2011
  • Acute myeloid leukemia..  9:280-317. 2011
  • Invasive breast cancer..  9:136-222. 2011
  • NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia..  9 Suppl 2:S1-25. 2011
  • Epithelial ovarian cancer..  9:82-113. 2011
  • NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes..  9:30-56. 2011
  • Controversies in Breast Cancer Screening Strategies. 2016